共和党在成本和监督问题上推动340B方案改革。 Republicans push 340B program reforms over cost and oversight concerns.

共和党立法者正在推动改革340B药品定价方案,该方案允许安全网医院和诊所按折扣价格购买药品。 Republican lawmakers are pushing for reforms to the 340B Drug Pricing Program, which lets safety-net hospitals and clinics buy drugs at discounted rates. 批评者认为,该方案已超出原定目的,使一些机构能够获利,并增加了纳税人和联邦方案的费用。 Critics argue the program has expanded beyond its original purpose, enabling some institutions to profit and increasing costs for taxpayers and federal programs. 关切问题包括监督松懈、资格可疑以及可能滥用折扣。 Concerns include lax oversight, questionable eligibility, and potential misuse of discounts. 支助者警告说,收紧规则会损害低收入和得不到充分服务的病人获得负担得起的药品的机会。 Supporters warn that tightening rules could harm access to affordable medications for low-income and underserved patients. 这场辩论反映了对保健支出和方案问责制的广泛关切,预计国会将在今后几个月内审议立法改革。 The debate reflects broader concerns about healthcare spending and program accountability, with Congress expected to consider legislative changes in the coming months.